Código QR (código de barras bidimensional)

Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity

Prostate cancer (PCa) is characterized as a “cold tumor” with limited immune responses, rendering the tumor resistant to immune checkpoint inhibitors (ICI). Therapeutic messenger RNA (mRNA) vaccines have emerged as a promising strategy to overcome this challenge by enhancing immune reactivity and si...

ver descrição completa

Na minha lista:
Principais autores: Zhen Xu, Ze-Xiu Xiao, Jing Wang, Hao-Wei Qiu, Fei Cao, Shi-Qiang Zhang, Yuan-Dong Xu, Han-Qi Lei, Heng Xia, Yun-Ru He, Gao-Feng Zha, Jun Pang
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis Group 2024-12-01
coleção:OncoImmunology
Assuntos:
Immunotherapy
lipid nanoparticles
mRNA vaccine
prostate cancer
tumor-associated antigens
Acesso em linha:https://www.tandfonline.com/doi/10.1080/2162402X.2024.2373526
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados